Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moshe Mittelman

Showing results (81-90 of 114) with videos related to

Pageof 12
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|July 7, 2020
Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life StudyEfrat Luttwak, Moshe E Gatt, Eyal Lebel, et al.
Frontiers in Immunology|November 16, 2020
Anti-CD20-Mediated B Cell Depletion Is Associated With Bone Preservation in Lymphoma Patients and Bone Mass Increase in MiceAlbert Kolomansky, Irit Kaye, Nathalie Ben-Califa, et al.
The Lancet. Haematology|December 16, 2017
Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trialMoshe Mittelman, Uwe Platzbecker, Boris Afanasyev, et al.
Theranostics|August 6, 2020
Erythropoietin receptor in B cells plays a role in bone remodeling in miceNaamit Deshet-Unger, Albert Kolomansky, Nathalie Ben-Califa, et al.
Cancer Medicine|December 19, 2022
Raising the standards of patient-centered outcomes research in myelodysplastic syndromes: Clinical utility and validation of the subscales of the QUALMS from the MDS-RIGHT projectFabio Efficace, Karin Koinig, Francesco Cottone, et al.
British Journal of Haematology|July 1, 2021
Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myelomaIrit Avivi, Roi Balaban, Tamir Shragai, et al.
Blood|April 13, 2006
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaBruce D Cheson, Peter L Greenberg, John M Bennett, et al.
Blood|August 4, 2025
A precision medicine approach to the myelodysplastic syndrome with isolated deletion 5q 50 years after its discoveryMarco Roncador, Elsa Bernard, Robert P Hasserjian, et al.
Haematologica|April 1, 2014
p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)Leonie Saft, Mohsen Karimi, Mehran Ghaderi, et al.
Blood Advances|September 7, 2021
Core set of patient-reported outcomes for myelodysplastic syndromes: an EUMDS Delphi study involving patients and hematologistsIgor Stojkov, Annette Conrads-Frank, Ursula Rochau, et al.
Pageof 12

Showing results (81-90 of 114) with videos related to

Sort By:
Pageof 12
Clinical Lymphoma, Myeloma & Leukemia|July 7, 2020
Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life StudyEfrat Luttwak, Moshe E Gatt, Eyal Lebel, et al.
Frontiers in Immunology|November 16, 2020
Anti-CD20-Mediated B Cell Depletion Is Associated With Bone Preservation in Lymphoma Patients and Bone Mass Increase in MiceAlbert Kolomansky, Irit Kaye, Nathalie Ben-Califa, et al.
The Lancet. Haematology|December 16, 2017
Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trialMoshe Mittelman, Uwe Platzbecker, Boris Afanasyev, et al.
Theranostics|August 6, 2020
Erythropoietin receptor in B cells plays a role in bone remodeling in miceNaamit Deshet-Unger, Albert Kolomansky, Nathalie Ben-Califa, et al.
Cancer Medicine|December 19, 2022
Raising the standards of patient-centered outcomes research in myelodysplastic syndromes: Clinical utility and validation of the subscales of the QUALMS from the MDS-RIGHT projectFabio Efficace, Karin Koinig, Francesco Cottone, et al.
British Journal of Haematology|July 1, 2021
Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myelomaIrit Avivi, Roi Balaban, Tamir Shragai, et al.
Blood|April 13, 2006
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaBruce D Cheson, Peter L Greenberg, John M Bennett, et al.
Blood|August 4, 2025
A precision medicine approach to the myelodysplastic syndrome with isolated deletion 5q 50 years after its discoveryMarco Roncador, Elsa Bernard, Robert P Hasserjian, et al.
Haematologica|April 1, 2014
p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)Leonie Saft, Mohsen Karimi, Mehran Ghaderi, et al.
Blood Advances|September 7, 2021
Core set of patient-reported outcomes for myelodysplastic syndromes: an EUMDS Delphi study involving patients and hematologistsIgor Stojkov, Annette Conrads-Frank, Ursula Rochau, et al.
Pageof 12